SKB 501
Alternative Names: SKB501Latest Information Update: 30 Oct 2025
At a glance
- Originator Kelun Pharmaceutical
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Oct 2025 SKB 501 is covered by patent protection (Kelun Biotech pipeline, October 2025)